
Can AI ever be âjust another teammateâ?
As AI grows more capable, HR leaders must carefully weigh its impact on team dynamics before treating it as just another teammate, says IMDâs Ginka Toegel....
by Faisal Hoque Published November 16, 2023 in Technology ⢠6 min read
Â
As the father of a cancer-surviving son, these days I often find myself investigating any new forms of treatment that may be of value for patients like him. Thatâs just one driving force behind my enthusiasm for the growing use of AI in the development and efficacy of immunotherapy.
One significant plus to AI across the spectrum of cancer treatments is a simple matter of speed. AI-enabled devices, including advanced computed tomography (CT) scans, magnetic resonance imaging (MRIs), and ultrasounds, can perform repetitive tasks more accurately and faster than human personnel.
Not only does that reduce the possibility of misdiagnosis, but it also shaves costs by recommending care before patientsâ conditions become more serious â and expensive.
One such example is an Israeli start-up that has created AI algorithms for diagnosing conditions including osteoporosis, brain hemorrhage, malignant tissue in breast mammography, and coronary aneurysms. The results come faster than those where humans are involved.
Even better, the accuracy of diagnosis improves. According to a recent report, AI has demonstrated 99% accuracy in evaluating and analyzing mammograms. This has made it possible to diagnose breast cancer more quickly, lowering the cost of diagnosis.
AIâs cost-saving potential is taking hold in other areas related to cancer care. At the Center for Cancer and Blood Disorders in Texas, oncologists employ clinical AI to help patients avoid unnecessary emergency room trips. AI enables care teams to predict which patients are likely to go into the ER in the next 30 daysâŻand recommends proactive steps oncologists and case managers can take to keep patients stable and out of emergency care altogether. Estimated savings: $3m.
âAI can analyze a patientâs genetic data to identify mutations that make the cancer more vulnerable to immunotherapy. This helps oncologists select the most effective treatment strategy for each patient.â
AIâs role in enhancing the effectiveness of immunotherapy, a game-changing cancer treatment, is particularly exciting and provocative. Unlike traditional cancer treatments such as chemotherapy and radiation, immunotherapy leverages the bodyâs immune system â a promising approach that has shown significant success in treating various types of cancer.
Currently, overall cure rates for advanced lung, breast, and colon cancer are typically less than 50%. This indicates a need for more focused treatment programs, ones that are suited to an individualâs cancer diagnosis and stage. This is where AI steps up to the plate.
Powered by machine learning, AI algorithms can analyze vast amounts of data, including genetic information, medical histories, and imaging scans. These algorithms can pinpoint patterns and correlations, particularly those that might be missed by human observers. This allows AI to predict the likely effectiveness of immunotherapy for individual patients. In turn, that can be used to develop personalized treatment plans and, further, more effective and longer-lasting patient outcomes.
For instance, AI can analyze a patientâs genetic data to identify mutations that make the cancer more vulnerable to immunotherapy. This helps oncologists select the most effective treatment strategy for each patient. Moreover, AI can predict potential side effects and adverse reactions, enabling doctors to take preventive measures and manage treatment more effectively without encountering unwanted results.
âAI can help show doctors which patients will get a bang for their buck through immunotherapy as well as those for whom the cost will essentially prove a waste of money.â
âOSAIRISâ can save many hours of physiciansâ time in preparing scans while also reducing patient wait time between referral for radiotherapy and treatment. The system works by significantly cutting the amount of time a doctor needs to spend drawing around healthy organs on scans before radiotherapy. Specialists can plan radiotherapy treatments approximately two-and-a-half times faster than if they were working alone, ensuring more patients can get treatment sooner and improving outcomes. (Source: Cambridge University Hospitals, June, 2023.)
Artificial intelligence has developed a treatment for an aggressive form of cancer in just 30 days. University of Toronto researchers worked with Insilico Medicine to develop potential treatment for hepatocellular carcinoma (HCC) using an AI drug discovery platform called Pharma. AI discovered a previously unknown treatment pathway. In a separate development, researchers from the University of British Columbia and BC Cancer have developed an artificial intelligence (AI) model that predicts cancer patient survival more accurately and with more readily available data than previous tools. The model is reportedly 80% accurate. (Source: Stacy Liberatore, Daily Mail, March, 2023.)
Artificial intelligence (AI) and machine learning platforms offer physicians the opportunity to optimize efficiency in revenue cycle management. By reviewing large amounts of health care financial data and leveraging that information to guide future claims to a more successful outcome, machine learning platforms have the potential to reduce the need for repeated insurance submissions and appeals, significantly improving the practiceâs clean claim rate. More efficient revenue cycle results can help reduce the potential financial burden on patients. (Source: Dan Lodder, OncLive, May 15, 2023.)
In one study, a team of researchers from several healthcare systems and universities discovered a new AI-derived biomarker, quantitative vessel tortuosity (QVT). Tumor-associated blood vessels are chaotically arranged and twisted, blocking the normal flow of blood and redirecting it to tumors, allowing them to grow even faster and spread throughout the body. The good news is that the QVT biomarker can help pinpoint these problematic tumors. Using routine imaging scans, physicians can now predict with far greater certainty which patients with lung cancer will respond to immunotherapy.
First and foremost, the findings, published recently in Science Advances, offer guidance for patients and their physicians making critical treatment decisions. In effect, AI can help doctors determine what sort of patient will respond to particular forms of immunotherapy â and those who will not.
AI protocols can also blunt the financial burden associated with immunotherapy. Given the staggering costs â roughly $200,000 a year per patient â the need to non-invasively identify potentially positive responses before beginning therapy becomes financially essential. AI can help show doctors which patients will get a bang for their buck through immunotherapy as well as those for whom the cost will essentially prove a waste of money.
But AIâs use in immunotherapy isnât limited to just highly individualized patient care. AI can also analyze global cancer research data. By doing so, it can identify new potential targets for immunotherapy, accelerating the development of new forms of treatment. AIâs ability to sift through vast amounts of research data and identify relevant findings is an invaluable tool in the overall fight against cancer.
Not surprisingly, the use of AI in immunotherapy is not without its challenges. For one thing, as sensitive patient information is used to develop AI algorithms, data privacy and security are significant concerns, including ownership of a patientâs healthcare records and history as well as whose data will be shared and under what circumstances. Patient consent also comes up.âŻAdditionally, transparency is essential for how AI draws its conclusions and treatment recommendations. This is particularly important to avoid systemic and repeated AI-generated mistakes and missteps due to inherent bias. Ethics are, understandably, also important. But for cancer patients, the use of AI in treatment such as immunotherapy is not only a matter of effective treatment and quality of life â but a growing source of hope.
This article is based on REINVENT: Navigating Business Transformation in a Hyperdigital EraâŻby Faisal Hoque (Fast Company Press, 2023), in association with IMD. All rights reserved. All proceeds from REINVENT book sales are pledged to multiple myeloma cancer research.
Related: 5 ways to kick bad habits by Faisal Hoque
Founder of SHADOKA and NextChapter
Faisal Hoque is the founder of SHADOKA, NextChapter, and other companies that focus on enabling sustainable and transformational changes. Throughout his career, he has developed more than 20 commercial business and technology platforms and worked with public and private sector giants such as the US Department of Defense, GE, MasterCard, American Express, Northrop Grumman, CACI, PepsiCo, IBM, Home Depot, Gartner, and JPMorgan Chase. He is a three-times winning Founder and CEO of Deloitte Technology Fast 50 and Deloitte Technology Fast 500â˘Â awards.
August 15, 2025 ⢠by Ginka Toegel in Innovation
As AI grows more capable, HR leaders must carefully weigh its impact on team dynamics before treating it as just another teammate, says IMDâs Ginka Toegel....
July 29, 2025 ⢠by Jean-François Manzoni in Innovation
Rohit Jawa, CEO of Hindustan Unilever, outlines how he is reshaping the companyâs strategy to meet the evolving needs of Indiaâs growing middle class, leveraging digital transformation, talent development, and a future-focused...
July 23, 2025 ⢠by Howard H. Yu in Innovation
To continue to grow at the exceptional rates we have seen over the last two decades, Chinese automakers need to conquer markets outside of China. However, they face significant strategic and cultural...
July 10, 2025 ⢠by Tomoko Yokoi, Michael R. Wade in Innovation
The healthcare and pharmaceutical sectors are experiencing radical evolution through artificial intelligence, driving competition, and improving clinical outcomes. IMD's AI Maturity Index highlights effective approaches from industry frontrunners like Bayer, Medtronic, and...
Explore first person business intelligence from top minds curated for a global executive audience